格隆汇10月9日｜天风证券研报指出，千红制药2025年H1实现营业收入8.62亿元，同比+0.72%；实现归 母净利润2.58亿元，同比+41.17%。公司制剂板块收入5.43亿元，同比-7.15%，制剂板块毛利率为 69.90%，同比+8.54pct，毛利率提升明显。截至2025年6月30日，公司已有四只创新药处于二期临床试 验或即将进入三期临床阶段，多只创新药处于一期临床试验阶段，还有相当数量的创新药正处于待批进 入临床研究或在临床前研究中。其中，原创一类新药QHRD107胶囊已完成Ⅱa期临床试验，且Ⅱa欧洲 血液学年会（EHA）顺利发表，目前正处于向CDE申请Ⅱb期临床研究阶段；原创一类新药QHRD106注 射液已完成Ⅱ期临床试验，目前正处于向CDE申请Ⅲ期临床研究阶段。考虑到公司2025H1收入增长稳 健与利润增长较快等因素，更新对公司2025-2027年营业收入预测为17.49/20.91/25.00亿元，更新对公司 2025-2027年归母净利润预测为4.59/4.23/4.75亿元。维持"增持"评级。 ...

天风证券研报指出，誉衡药业2025年H1实现归母净利润1.34亿元，同比+7.56%；降本增效继续推进， 成效持续显现。在资产质量方面，公司资产负债率由去年同期的31.66%下降至28.70%，公司资产负债 结构持续优化，抗风险能力继续增强。2025H1公司与兴和制药就佩玛贝特片签订了共同推广协议、与 卫材（中国）就甲钴胺注射液签订了市场推广服务协议。佩玛贝特片作为新一代贝特类药物，具有广阔 市场前景。公司推广佩玛贝特片，将丰富公司的产品管线，有望增加公司的营业收入及利润，增强公司 在心脑血管领域的竞争力；此外，将进一步提升公司的专业化学术推广能力，为未来更多的产品合作奠 定基础。维持"买入"评级。 ...

"总体上看，未来一段时间央行会综合运用买断式逆回购、MLF两项政策工具，持续向市场注入中期流 动性。"王青认为，这在助力政府债券发行，引导金融机构加大货币信贷投放力度的同时，也将释放数 量型政策工具持续加力信号，显示货币政策延续支持性立场。 央行货币政策委员会第三季度例会提到，建议加强货币政策调控，提高前瞻性、针对性、有效性，根据 国内外经济金融形势和金融市场运行情况，把握好政策实施的力度和节奏，抓好各项货币政策措施执 行，充分释放政策效应。保持流动性充裕，引导金融机构加大货币信贷投放力度，使社会融资规模、货 币供应量增长同经济增长、价格总水平预期目标相匹配。 目前，央行基础货币投放的渠道已较为丰富。市场人士预计，央行将通过质押式逆回购维持短期流动性 平衡，MLF和买断式逆回购提供中期流动性，降准叠加恢复国债买卖向市场注入长期流动性，以保持 市场流动性合理充裕。 10月9日，央行以固定数量、利率招标、多重价位中标方式开展1.1万亿元买断式逆回购操作，期限为3 个月（91天），加量续作3000亿元。 "十一"长假后，银行间市场资金回笼压力明显加大。10月9日至10日，公开市场逆回购到期量分别为 20633亿元和 ...

天风证券（601162）发布研报称，维持和誉-B(02256)"买入"评级，预计公司2025-2027年的营业收入分 别为6.30亿元、6.85亿元和6.37亿元，归母净利润为0.45亿元、0.70亿元和1.02亿元。公司的PD-L1小分 子抑制剂ABSK043联合KRASG12C抑制剂戈来雷塞片开展联合用药治疗KRASG12C突变的NSCLC的临 床研究申请获CDE批准。此前，公司已经与艾力斯就联合用药达成了合作协议。 报告中称，公司多项核心资产迎来里程碑，发展进入密集催化新阶段。1)KRAS-G12D抑制剂 ABSK141，在小鼠等动物模型中展现了同类最佳口服生物利用度，GLP毒理学研究中展现出良好的安 全性特征，有望于2025年下半年获得IND批准;2)Pan-KRAS inhibitor ABSK211具有泛KRAS抑制剂具有 潜在同类最佳的效力，对多种KRAS突变具有广泛抑制作用，且效力卓越，同时不损伤KRAS非依赖性 细胞系，预计2026年进入临床阶段;3)CSF-1R抑制剂ABSK021(Pimicotinib)的TGCT适应症预计于2025H2 向美国FDA递交NDA。4)靶向两个泛癌靶点的双 ...

报告中称，公司多项核心资产迎来里程碑，发展进入密集催化新阶段。1)KRAS-G12D抑制剂 ABSK141，在小鼠等动物模型中展现了同类最佳口服生物利用度，GLP毒理学研究中展现出良好的安 全性特征，有望于2025年下半年获得IND批准;2)Pan-KRAS inhibitor ABSK211具有泛KRAS抑制剂具有 潜在同类最佳的效力，对多种KRAS突变具有广泛抑制作用，且效力卓越，同时不损伤KRAS非依赖性 细胞系，预计2026年进入临床阶段;3)CSF-1R抑制剂ABSK021(Pimicotinib)的TGCT适应症预计于2025H2 向美国FDA递交NDA。4)靶向两个泛癌靶点的双特异性抗体偶联药物(BsADC)预计于2026年初获得临床 前候选药物，该设计可协同发挥双靶点的治疗优势，通过共表达调控，降低各靶点在正常组织中的副作 用。 智通财经APP获悉，天风证券发布研报称，维持和誉-B(02256)"买入"评级，预计公司2025-2027年的营 业收入分别为6.30亿元、6.85亿元和6.37亿元，归母净利润为0.45亿元、0.70亿元和1.02亿元。公司的 PD-L1小分子抑制剂ABSK043联 ...

Core Viewpoint - The recent approval of a new 100mg specification for SKB264 by NMPA is expected to enhance treatment accessibility and convenience for patients with advanced breast cancer and non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Research and Product Development - SKB264's two key clinical studies have been selected for presentation at the 2025 ESMO conference, with the OptiTROP-Lung04 study being featured in the Presidential Symposium, highlighting its potential in treating EGFR-mutant NSCLC [1] - The company anticipates significant revenue growth, projecting revenues of 2.084 billion, 2.876 billion, and 4.663 billion yuan for the years 2025, 2026, and 2027 respectively [1] - SKB264 has received approval for the treatment of EGFR-mutant NSCLC in China and is making progress in earlier lines of treatment, with a New Drug Application (NDA) for 2L NSCLC submitted and prioritized for review [1] Group 2: Efficacy in Rare Mutations and Other Indications - SKB264 has shown promising results in treating rare EGFR mutations, achieving an overall response rate (ORR) of 35.7% and a disease control rate (DCR) of 85.7% in a Phase II study [2] - Ongoing clinical trials for SKB264 in various NSCLC settings are demonstrating superior efficacy compared to other investigational drugs and existing therapies [2] Group 3: Breast Cancer Applications - SKB264 has been approved for use in triple-negative breast cancer (TNBC) and is under review for HR+/HER2- breast cancer, with the NDA based on the successful OptiTROP-Breast02 study [3] - The OptiTROP-Breast02 study has met its primary endpoint, showing significant improvements in progression-free survival (PFS) and a positive trend in overall survival (OS) for HR+/HER2- breast cancer patients [3]

天风证券研报指出，根据经济复苏与市场流动性，可以把投资主线降维为三个方向：（1）Deepseek突 破与开源引领的科技AI。（2）内外共振，经济逐步修复，牛市主线风格"强者恒强"，但周期后半段易 有所表现。（3）低估红利继续崛起。牛市初期资金更偏好少数高景气赛道，后期资金抱团聚焦主线， 新增资金获利难度提升，而周期股又具备低估值、高贝塔的属性，易随着基本面回暖的深化而发挥较好 的业绩弹性，获得增量资金青睐。 NO.3中金：节后A股有望延续稳健表现 震荡上行行情仍在延续 ｜2025年10月9日 星期四｜ NO.1中信建投：建议关注金银铜等有色板块投资机遇 中信建投证券研报认为，金银等贵金属和加密货币在国庆中秋假期迎来大涨。国际金价大涨的背后主要 是由美国政府"停摆"引发的短期波动、日本政治更迭带来的短期不确定性、美联储持续降息预期和全球 央行持续购金共同推动的。美国政府关门扰动、未来降息和衰退的预期使得全球投资者对美元信用和美 国主权债务的担忧进一步上升，这推动了金银等贵金属和比特币价格进一步走高。与此同时，供给短缺 和算力革命逻辑下，铜价近期也明显走强。建议关注金银铜等有色板块投资机遇。 NO.2天风证券：周 ...

Core Insights - The company reported a revenue of 1.1 billion yuan for H1 2025, a decrease of 9.97% year-on-year, while the net profit attributable to shareholders increased by 7.56% to 134 million yuan [1] - Cost reduction and efficiency improvement measures are showing positive results, with sales expenses down 31.28% to 294 million yuan and management expenses down 21.58% to 56.75 million yuan [2] - The company signed promotional agreements for Pemabate tablets, which are expected to enhance its product pipeline and competitiveness in the cardiovascular field [3] - Revenue forecasts for 2025-2027 have been adjusted to 2.364 billion, 2.464 billion, and 2.661 billion yuan, while net profit forecasts have been increased to 258 million, 282 million, and 318 million yuan [4] Financial Performance - H1 2025 revenue: 1.1 billion yuan, down 9.97% year-on-year [1] - H1 2025 net profit: 134 million yuan, up 7.56% year-on-year [1] - H1 2025 non-recurring net profit: 107 million yuan, up 13.28% year-on-year [1] Cost Management - Sales expenses decreased from 428 million yuan to 294 million yuan, a reduction of 31.28% [2] - Sales expense ratio fell from 35.06% in H1 2024 to 26.76% [2] - Management expenses decreased from 72.37 million yuan to 56.75 million yuan, a reduction of 21.58% [2] - Asset-liability ratio improved from 31.66% to 28.70% [2] Product Development - The company signed a joint promotion agreement for Pemabate tablets, which have a promising market outlook [3] - Pemabate tablets are the first new selective PPARα modulator approved in China, aimed at lowering triglyceride levels [3] - The promotion of Pemabate tablets is expected to enhance the company's revenue and profit, as well as its academic promotion capabilities [3] Revenue and Profit Forecast - Adjusted revenue forecasts for 2025-2027: 2.364 billion, 2.464 billion, and 2.661 billion yuan [4] - Adjusted net profit forecasts for 2025-2027: 258 million, 282 million, and 318 million yuan [4]

天风证券10月1日发布研报称，调整兴业科技(002674.HK)盈利预测，维持"增持"评级。考虑内销疲软， 小幅调整盈利预测，预计25-27年归母净利1.4、1.8、2.0亿元（原值1.5、1.8、2.3亿元）；PE分别为 32x、26x、23x。 ...

Core Viewpoint - Tianfeng Securities has slightly adjusted the profit forecast for Anta Sports, expecting net profit attributable to shareholders to be 13.6 billion RMB, 15.5 billion RMB, and 17.3 billion RMB for the years 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 18x, 15x, and 14x, maintaining a "Buy" rating Brand Performance - Mature Brand: Anta brand is expected to achieve revenue of 17 billion RMB in H1 2025, a year-on-year increase of 5.4%, accounting for approximately 44% of total revenue, with a gross margin of 54.9% [1] - Growth Brand: FILA brand is projected to generate revenue of 14.2 billion RMB in H1 2025, a year-on-year increase of 8.6%, representing about 37% of total revenue, with a gross margin of 68% [1] - Emerging Brand Portfolio: Other brands (including DESCENTE and KOLON SPORT) are expected to achieve revenue of 7.4 billion RMB in H1 2025, a year-on-year increase of 61.1%, increasing their revenue share from approximately 13% to about 19%, with a gross margin of 73.9% [1] Channel Performance - DTC: Expected revenue of 9.4 billion RMB in H1 2025, a year-on-year increase of 5.3%, accounting for about 56% of total revenue [2] - E-commerce: Anticipated revenue of 6.1 billion RMB in H1 2025, a year-on-year increase of 10.1%, representing approximately 36% of total revenue [2] - Traditional Wholesale and Others: Expected revenue of 1.4 billion RMB in H1 2025, accounting for about 8% of total revenue [3] Strategy and Outlook - The company will continue to implement a "single focus, multi-brand, globalization" strategy in H1 2025, driving growth through dual core brands [4] - Anta brand will deepen its transformation and promote innovation in business models and specialized stores, while FILA will focus on golf and tennis to build a core product matrix [4] - Emerging brands like DESCENTE and KOLON SPORT are expected to maintain rapid growth, with global expansion covering Asia, Europe, and America [4] - The company is enhancing digital integration and initiating AI strategic layouts to drive material research and process innovation [4] - A 3-5 year revitalization plan has been established for the JACK WOLFSKIN brand to reshape its product system [4]